Page 1,494«..1020..1,4931,4941,4951,496..1,5001,510..»

India’s Advancells Reports Successful Reversal of MS in Single Patient Using Stem Cell Therapy – Multiple Sclerosis News Today

Posted: August 12, 2017 at 6:42 am

Advancellssays its stem cell-based therapy completely reversed multiple sclerosis (MS) in an Indian pilot trial with only one MS patient.

The patient, Rahul Gupta, was diagnosed with MS seven years ago and has since suffered multiple relapses. His disease was progressing fast and he was quickly losing his ability to walk. Gupta, who lives in New Zealand, approached Advancells a company based in the Indian state of Uttar Pradesh that specializes in the use of stem cells for therapeutic purposes.

After my last relapse, I became determined to look for alternative treatments for multiple sclerosis,Gupta said in a press release. I started looking on the net and found that stem-cell therapy [offers] hope for people suffering with MS [and] that it is safe and would not harm me in any way. I was determined to undergo stem-cell treatment, as my illness was progressing very quickly.

Gupta enrolled inAdvancells adult stem-cell therapy program as the trials single patient. In the procedure carried outin June at a New Delhi clinic doctors isolated stem cells from his bone marrow and re-infused them back into the patientat specific points. Apart from this procedure, Gupta underwent only physiotherapy and a dietary routine.

Straight after the treatment I saw major improvements, he said. I could walk a lot better, could climb stairs which I was unable to do after 2012 and even go on the treadmill.

Dr. Lipi Singh, head of technology at Advancells, said the company is frequently approached by MS patients from around the world who want to participate in its program.

Patient selection is a key criterion for us and Rahul suited the criteria perfectly, Singh said. He is young and still at a moderate level of the disease and in a very positive frame of mind. Patients at this stage are best suited for this kind of treatment and thus we decided to accept him as a pilot case.

Singh now expects to review Guptas response sometime this fall.

It will take approximately three months for us to review changes in the magnetic resonance imaging of the patient, but the drastic changes in symptoms clearly are an indication of the fact that the treatment is working and could become a hope for millions of patients across the world who are suffering from this disease. Singh said.

He added: This is a good start to a lengthy research phase, but it seems that we are on the right track and hopefully we will be able to make a significant contribution in eradicating not only MS but a host of untreatable diseases existing today.

Read the original:
India's Advancells Reports Successful Reversal of MS in Single Patient Using Stem Cell Therapy - Multiple Sclerosis News Today

Posted in Stem Cell Treatments | Comments Off on India’s Advancells Reports Successful Reversal of MS in Single Patient Using Stem Cell Therapy – Multiple Sclerosis News Today

A Chip That Reprograms Cells Helps Healing, At Least In Mice – Wyoming Public Media

Posted: August 12, 2017 at 6:41 am

Scientists have created an electronic wafer that reprogrammed damaged skin cells on a mouse's leg to grow new blood vessels and help a wound heal.

One day, creator Chandan Sen hopes, it could be used to be used to treat wounds on humans. But that day is a long way off as are many other regeneration technologies in the works. Like Sen, some scientists have begun trying to directly reprogram one cell type into another for healing, while others are attempting to build organs or tissues from stem cells and organ-shaped scaffolding.

But other scientists have greeted Sen's mouse experiment, published in Nature Nanotechnology on Monday, with extreme skepticism. "My impression is that there's a lot of hyperbole here," says Sean Morrison, a stem cell researcher at the University of Texas Southwestern Medical Center. "The idea you can [reprogram] a limited number of cells in the skin and improve blood flow to an entire limb I think it's a pretty fantastic claim. I find it hard to believe."

When the device is placed on live skin and activated, it sends a small electrical pulse onto the skin cells' membrane, which opens a tiny window on the cell surface. "It's about 2 percent of the cell membrane," says Sen, who is a researcher in regenerative medicine at Ohio State University. Then, using a microscopic chute, the chip shoots new genetic code through that window and into the cell where it can begin reprogramming the cell for a new fate.

Sen says the whole process takes less than 0.1 seconds and can reprogram the cells resting underneath the device, which is about the size of a big toenail. The best part is that it's able to successfully deliver its genetic payload almost 100 percent of the time, he says. "No other gene delivery technique can deliver over 98 percent efficiency. That is our triumph."

To test the device's healing capabilities, Sen and his colleagues took a few mice with damaged leg arteries and placed the chip on the skin near the damaged artery. That reprogrammed a centimeter or two of skin to turn into blood vessel cells. Sen says the cells that received the reprogramming genes actually started replicating the reprogramming code that the researchers originally inserted in the chip, repackaging it and sending it out to other nearby cells. And that initiated the growth of a new network of blood vessels in the leg that replaced the function of the original, damaged artery, the researchers say. "Not only did we make new cells, but those cells reorganized to make functional blood vessels that plumb with the existing vasculature and carry blood," Sen says. That was enough for the leg to fully recover. Injured mice that didn't get the chip never healed.

When the researchers used the chip on healthy legs, no new blood vessels formed. Sen says because injured mouse legs were was able to incorporate the chip's reprogramming code into the ongoing attempt to heal.

That idea hasn't quite been accepted by other researchers, however. "It's just a hand waving argument," Morrison says. "It could be true, but there's no evidence that reprogramming works differently in an injured tissue versus a non-injured tissue."

What's more, the role of exosomes, the vesicles that supposedly transmit the reprogramming command to other cells, has been contentious in medical science. "There are all manners of claims of these vesicles. It's not clear what these things are, and if it's a real biological process or if it's debris," Morrison says. "In my lab, we would want to do a lot more characterization of these exosomes before we make any claims like this."

Sen says that the theory that introduced reprogramming code from the chip or any other gene delivery method does need more work, but he isn't deterred by the criticism. "This clearly is a new conceptual development, and skepticism is understandable," he says. But he is steadfast in his confidence about the role of reprogrammed exosomes. When the researchers extracted the vesicles and injected them into skin cells in the lab, Sen says those cells converted into blood vessel cells in the petri dish. "I believe this is definitive evidence supporting that [these exosomes] may induce cell conversion."

Even if the device works as well as Sen and his colleagues hope it does, they only tested it on mice. Repairing deeper injuries, like vital organ damage, would also require inserting the chip into the body to reach the wound site. It has a long way to go before it can ever be considered for use on humans. Right now, scientists can only directly reprogram adult cells into a limited selection of other cell types like muscle, neurons and blood vessel cells. It'll be many years before scientists understand how to reprogram one cell type to become part of any of our other, many tissues.

Still, Morrison says the chip is an interesting bit of technology. "It's a cool idea, being able to release [genetic code] through nano channels," he says. "There may be applications where that's advantageous in some way in the future."

Read more from the original source:
A Chip That Reprograms Cells Helps Healing, At Least In Mice - Wyoming Public Media

Posted in Wyoming Stem Cells | Comments Off on A Chip That Reprograms Cells Helps Healing, At Least In Mice – Wyoming Public Media

Adult Stem Cells’ Role in Disease Management and Anti-Aging

Posted: August 12, 2017 at 6:41 am

By Dr. Mercola

Since time immemorial, man has searched for the Fountain of Youth. Nothing has changed in that regard, but the methods of inquiry and discovery have certainly progressed.

Some of these ideas rival even the most outlandish sci-fi scenarios imaginable, up to and including the transfer of your consciousness into a bionic body.1 Personally, I dont want to veer too far from the natural order of things.

But the technology and science enthusiast in me cant help but be intrigued by the ideas and radical advances in the field of extreme life extension. One of the most promising techniques in this field, from my perspective, revolves around the use of adult stem cells.

Adult stem cells are undifferentiated cells found throughout your body. They multiply and replace cells as needed, in order to regenerate damaged tissues. Their value, in terms of anti-aging and life extension, centers around their ability to self-renew indefinitely, and their ability to generate every type of cell needed for the organ from which it originates.

Dr. Bryant Villeponteau, author of Decoding Longevity, is a leading researcher in novel anti-aging therapies involving stem cells. Hes been a pioneer in this area for over three decades.

Personally, I believe that stem cell technology could have a dramatic influence on our ability to live longer and replace some of our failing parts, which is the inevitable result of the aging process. With an interest in aging and longevity, Dr. Villeponteau started out by studying developmental biology.

If we could understand development, we could understand aging, he says.

Later, his interest turned more toward the gene regulation aspects. While working as a professor at the University of Michigan at the Institute of Gerontology, he received, and accepted, a job offer from Geron Corporationa Bay Area startup, in the early 90s.

They were working on telomerase, which I was pretty excited about at the time. I joined them when they first started, he says. We had an all-out engagement there to clone human telomerase. It had been cloned in other animals but not in humans or mammals.

Your body is made up of 10 trillion cells, each of which contains a nucleus. Inside the nucleus are the chromosomes that contain your genes. The chromosome is made up of two arms, and each arm contains a single molecule DNA, which is essentially a string of beads made up of units called bases.

A typical DNA molecule is about 100 million bases long. Its curled up like slinky, extending from one end of the chromosome to the other. At the very tip of each arm of the chromosome is whats called a telomere.

If you were to unravel the tip of the chromosome, a telomere is about 15,000 bases long at the moment of conception in the womb. Immediately after conception, your cells begin to divide, and your telomeres begin to shorten each time the cell divides. Once your telomeres have been reduced to about 5,000 bases, you essentially die of old age.

Telomerase is an enzyme that is involved in repairing the ends of the chromosomes, i.e. the telomere, thereby preventing it from shortening.

What you have to know about telomerase is that its only on in embryonic cells. In adult cells, its totally, for the most part, turned off, with the exception of adult stem cells, Dr. Villeponteau explains. Adult stem cells have some telomerase not full and not like the embryonic stem cells, but they do have some telomerase activity.

At Geron, Dr. Villeponteau worked on a program to isolate human telomerase. They were the first industrial lab to do so, and successfully at that. The founder of Geron was Michael Westnow known for his pioneering work with embryonic stem cells. In 94-95, West began searching for another product to add to Gerons arsenal besides telomerase. He honed in on stem cells, recognizing their incredible potential for turning regeneration of body tissues into a practical reality.

He identified several groups that were working on the isolation of human stem cells, Dr. Villeponteau says. He put together a collaborative agreement with these people and part-funding from Geron. That bore fruit later in the 90s. Thats how Geron became both the telomerase and the stem cell king it was because of that early support of the stem cell research. They had lines of stem cell, embryonic stem cells, before anybody else did.

I was involved in a lot of that initial research. But what I came away with was that these embryonic stem cells, as good as they were, had problems too. Because you had to isolate them, you had to grow them, and then you had to put them into a foreign body, if they were going to be useful. That means you have to worry about immunity, because its a different type of somebody elses cells. That was a problem.

The other problem was that it was not that easy and straightforward to differentiate these embryonic stem cells the way you want them. I started to be more interested at that point in adult stem cells.

Most of the research currently being done, both in academia and industrial labs, revolves around either embryonic stem cells, or a second type called induced pluripotent stem cells (iPS). Dr. Villeponteau, on the other hand, believes adult stem cells are the easiest and most efficient way to achieve results.

That said, adult stem cells do have their drawbacks. While theyre your own cells, which eliminates the problem of immune-related issues, theres just not enough of them. Especially as you get older, there are fewer and fewer adult stem cells, and they tend to become increasingly dysfunctional too. Yet another hurdle is that they dont form the tissues that they need to form...

To solve such issues, Dr. Villeponteau has created a company with the technology and expertise to amplify your adult stem cells a million-fold or more, while still maintaining their ability to differentiate all the different cell types, and without causing the cells to age. Again, it is the adult stem cells ability to potentially cure, or at least ameliorate, many of our age-related diseases by regenerating tissue that makes this field so exciting.

I was initially intrigued with the principles of using telomerase to potentially extend human lifespan. But in talking to a few other clinicians, I became aware that using a generic process to influence the entire body raises potentially serious concerns. Dr. Villeponteaus amplification process of human adult stem cells, however, appears to bypass such concerns as its targeted to one cell type. He explains:

Heres the issue: I think, with telomerase activation systemically, it probably doesnt do much good, because 99 percent of your cells are not going to be affected, nor should they be. You dont even want them to be, because the somatic cells in the body, the cells that do all the work muscle, nerves, and all of that have a natural lifespan. Maybe you can do certain things to extend [their lifespan] a little bit. But youre going to do only a little on the margins. Theyre going to be dying and they have to be regenerated. There has to be a regeneration process.

They used to think that certain tissues like the brain and heart muscle didnt have any stem cells; didnt have any new growth. Thats not true. Now weve found that they do have them. In the case of neuro [brain cells], it is very important for memory that you have this capability. I think where the telomerase activation really helps, even taken systemically, is in the stem cell compartment because it would help with your own stem cells.

We have a product that weve been selling commercially... to stimulate stem cell growth and maintenance of the stem cells, and telomere function is part of it... [A]ging itself and stem cells are multi-faceted and multi-pathway. You really have to attack it from different pathways. Theres no magic bullet in its treatment. You have to get in multiple ways, because aging is a process that [involves] multiple pathways.

Dr. Villeponteau uses skin as an example to illustrate the potential benefits of adult stem cells, as your skin can be used as a cosmetic guidepost for how old you are. As you get older, your skin starts to thin and lose its elasticity. This is what causes your skin to wrinkle and sag. Now, your skin is constantly renewing itself; shedding old cells as new cells are created underneath. Adult stem cells are responsible for these new skin cells being born.

As mentioned earlier, with age, your adult stem cells are reduced in number. They also become increasingly dysfunctional. As a result, the turnover in your skin slows down by about half. If you were able to keep the regeneration of skin tissue at more youthful levels by the addition of adult stem cells, youd be able to maintain youthful-looking skin longer. While this may sound too good to be true, Dr. Villeponteau points to experimental and practical evidence showing that body organs can be repaired using this technology. As for stopping the clock on general aging, however, the results are less clear.

For general aging, are we going to be able to replace your stem cells by, lets say, IV? We dont know how much good we can do. But there has been one rat experiment thats been done. They were able to extend the lifespan by adding IV stem cell population, he says.

There are three major types of stem cell populations, each with their own set of pros and cons:

While potent, their immaturity also poses problems. Its difficult to program them to develop into later-stage tissues. Its also difficult to find a way for them to form the specific tissue types that you want, because theyre further removed from those individual tissues say, liver, brain, or muscle tissue. Embryonic stem cells also have cancer potential because they form keratomas, although thats rare. And, since they are not your own cells, they may cause an immune reaction.

However, this too has its problems. On the upside, it eliminates the issue of an immune reaction, since its your own cells. But it still has the potential to promote tumor growth. As explained by Dr. Villeponteau, whenever you insert genes into a genome, you run the risk of putting it near a cancer gene, thereby generating cancer. There are also difficulties in being able to differentiate them into the various tissues you might need. Still, its an exciting area where lots of research is being done.

Very recently, there was one group that was able to take, I think, seven chemical drugs and convert a small proportion of the fibroblast into these iPS cellsdoing it just chemically and not using any genes. Of course, thats much safer. But we dont know the full impact of what thats going to mean yet, Dr. Villeponteau says.

In the US, its illegal to take out a cell, amplify it, and then put it back into the human body. The FDA considers that as a drug. However, it is legal to take bone marrow, for example, and isolate the stem cells. As long as you dont treat the cells with any kind of drug, or try to grow them, you can then legally put them back in, in a purified, concentrated form. Such treatments already exist, both in the US and abroad.

One of the most common treatments using isolated adult stem cells is for knee injuries. According to Dr. Villeponteau, theyre achieving very good results doing that, and many are actually cured. Adult stem cell therapy has also been successfully used in people with back problems, and it appears particularly effective for joint problems and bone growth. Dr. Villeponteau even used adult stem cells to treat bone loss around one of his front teeth, with good results.

He also believes it could be successfully used in the treatment of diabetes, and for recreating the human pancreas and perhaps even the heart. Another area he believes will eventually benefit from adult stem cell technology is in the general reconditioning of your circulatory systemyour arteries, veins and capillaries. Autoimmune diseases and multiple sclerosis (MS) may also benefit. At present, theres a doctor in Utah who claims to be using adult stem cells on stroke patients; successfully regenerating brain function. Stem cells have also been used in cancer patients for the past two decades.

Cancer patients, if they get high levels of radiation to kill off the cancer, it also kills off blood-forming stem cells. What theyve been doing in some places, for 20 years now, is to take a sample of your bone marrow and then replace it after the chemotherapy or the radiation therapy to regrow your immune system quickly. They can do that several times. That allows you to go to a much higher dosage of radiation that you would otherwise not be able to survive.

Another novel technology that also makes use of stem cells is 3D-printing architecture, where iPS cells or embryonic stem cells (not adult stem cells) are used to recreate an organ using a 3D printer. This too is something straight out of a science fiction movie, but it does work, and its legal. Theyve successfully replicated an esophagus for example, as well as human ears. Its really only a matter of time before they figure out how to replicate more complex organs, such as kidneys, pancreas, livers and hearts using this technology.

When I think about aggressive future efforts to reverse the aging process, nanotech comes to mind. In talking to Dr. Villeponteau, I believe the technology hes working on is akin to biological nanotech. Rather than creating synthetic nanobots to repair tissues, it would seem far wiser to focus on the already intrinsic intelligence of the human body, which already knows how to use adult stem cells to perform such tasks.

Theres no telling how long it will take for this kind of technology to be perfected, but research is certainly moving ahead at near-breakneck speed. Dr. Villeponteau believes adult stem cells are the fastest way to make some real headway in the areas of cellular regeneration and life extension.

Until then, you can certainly add many years, likely decades, to your life simply by eating right, exercising (which promotes the production of muscle stem cells, by the way) and living an otherwise clean and healthy lifestyle. Extreme life extension, on the other hand, is a different matter.

I think you can add 20 years to your life now if you eat right, take the right supplements, and exercise. Youd delay diseases, but thats all youre going to get. Youre not going to get extreme changes. To do that, you need real science, he says.

Dr. Villeponteaus book, Decoding Longevity, covers preventive strategies to prolong your life, mainly diet, exercise, and supplementsalthough he admittedly also includes some drugs. A portion of the book also covers future developments in the area of more radical life extension, such as stem cell technology. To keep abreast of advancements in this area, you can check out his company website at http://www.centagen.com.

More here:
Adult Stem Cells' Role in Disease Management and Anti-Aging

Posted in Utah Stem Cells | Comments Off on Adult Stem Cells’ Role in Disease Management and Anti-Aging

Fast facts about cloning – WPSD Local 6

Posted: August 12, 2017 at 6:41 am

(CNN) -- Here's some background information aboutcloning, a process of creating an identical copy of an original.

Facts: Reproductive Cloning is the process of making a full living copy of an organism. Reproductive cloning of animals transplants nuclei from body cells into eggs that have had their nucleus removed. That egg is then stimulated to divide using an electrical charge and is implanted into the uterus of a female.

Therapeutic Cloningis the process where nuclear transplantation of a patient's own cells makes an oocyte from which immune-compatible cells (especiallystem cells) can be derived for transplant. These cells are stimulated to divide and are grown in a Petri dish rather than in the uterus.

Timeline: 1952 - Scientists demonstrate they can remove the nucleus from a frog's egg, replace it with the nucleus of an embryonic frog cell, and get the egg to develop into a tadpole.

1975 -Scientists get tadpoles after transferring cell nuclei from adult frogs.

1986 -Sheep cloned by nuclear transfer from embryonic cells.

February 22, 1997 -Scientists reveal Dolly the sheep, the first mammal to be cloned from cells of an adult animal. She was actually born on July 5, 1996.

1998 -More than 50 mice are reported cloned from a single mouse over several generations. Eight calves are cloned from a cow.

2000 -Pigs and goats are reported cloned from adult cells.

2001 -Advanced Cell Technology of Worcester, Massachusetts, says it produced a six-cell cloned human embryo, in research aimed at harvesting stem cells.

2001 -Five bulls are cloned from a champion bull, Full Flush.

2002 -Rabbits and a kitten are reported cloned from adult cells.

December 27, 2002 - Clonaid claims to produce first human clone, a baby girl, Eve.

January 23, 2003 -Clonaid claims to have cloned the first baby boy. The baby was allegedly cloned from tissue taken from the Japanese couple's comatose 2-year-old boy, who was killed in an accident in 2001. Clonaid has never provided physical evidence of the cloning.

February 14, 2003 -The Roslin Institute confirms that Dolly, the world's first cloned mammal, was euthanized after being diagnosed with progressive lung disease. She was 6 years old.

May 4, 2003 -The first mule is cloned at the University of Idaho, named Idaho Gem.

June 9, 2003 -Researchers Gordon Woods and Dirk Vanderwall from the University of Idaho and Ken White from Utah State University claim to have cloned a second mule.

August 6, 2003 -Italian scientists at the Laboratory of Reproductive Technology in Cremona, Italy, say they have created the world's first cloned horse, Prometea, from an adult cell taken from the horse who gave birth to her.

September 25, 2003 -French scientists at the National Institute of Agricultural Research at Joy en Josas, France, become the first to clone rats.

February 12, 2004 -South Korean researchers report they have created human embryos through cloning and extracted embryonic stem cells. Findings by a team of researchers were presented to South Korean scientists and describe in detail the process of how to create human embryos by cloning. The report says the scientists used eggs donated by Korean women. An investigative panel concludes in 2006 that South Korean scientist Woo Suk Hwang's human stem cell cloning research was faked.

August 3, 2005 -South Korean researchers announce they have successfully cloned a dog, an Afghan hound named Snuppy.

December 8, 2008-April 4, 2009 -Five cloned puppies from Trakr, a German Shepherd Sept.11 Ground Zero rescue dog, are born.

May 2009 -Clone of Tailor Fit, a two-time quarter horse world champion, is born, one of several cloned horses born that year.

September 29, 2011 -At South Korea's Incheon Airport, seven "super clone" sniffer-dogs are dispatched to detect contraband luggage. They are all golden Labrador Retrievers that are genetically identical to "Chase," who was the top drug detention canine until he retired in 2007.

May 15, 2013 -Oregon Health & Science University researchers report in the journal Cell that they have created embryonic stem cells through cloning. Shoukhrat Mitalipov and the biologistsproduced human embryos using skin cells, and then used the embryos to produce stem cell lines.

April 2014 -For the first time,cloning technologies have been used to generate stem cells that are genetically matched to adult patients.Researchers put the nucleus of an adult skin cell inside an egg, and that reconstructed egg went through the initial stages of embryonic development, according to research published this month.

The-CNN-Wire & 2017 Cable News Network, Inc., a Time Warner Company. All rights reserved.

Read the original post:
Fast facts about cloning - WPSD Local 6

Posted in Utah Stem Cells | Comments Off on Fast facts about cloning – WPSD Local 6

Reinventing tissue regeneration, one layer at a time – MedCity News

Posted: August 12, 2017 at 6:41 am

There are some fancy tools out there for repairing skin, from 3D bioprinting, scaffolds and matrices to spray guns that rain stem cells directly onto a wound. Doctors in Brazil are even experimenting with sterilized Tilapia fish skin as a novel dressing for burns.

Creativity is nice, but that alone wont save patients battling through the most critical hours of their lives. Denver Lough, an M.D./Ph.D., saw this first hand while working at the Johns Hopkins Plastic and Reconstructive Surgery Program. Nothing was truly getting the job done.

Name one regenerative medicine product or company thats out there that actually truly regenerates anything, Lough challenged in a recent phone interview. Not, we grow keratinocytes, or we can turn a cell into an osteogenic lineage but really; does this grow full thickness tissue? Theres really not one out there and theres certainly not one thats being used clinically right now for skin regeneration.

Now CEO and CSO of PolarityTE, Lough believes the fundamental approach to tissue regeneration is taught wrong. And thats why, after all these years, skin healing remains imperfect.

Biotechs working in this field have zoomed in on individual cells, he said, working to culture and manipulate stem cells or to find the right recipe for growth factors that can guide differentiation. Thats not how biology works, Lough contests.

[Biology] works through cells interacting with each other, having gradients, having interfaces, having polarity. A cell needs to know what way is up, what way is down, he said.When you pull a single cell out of a tissue and try to command it to go down a pathway, you negate all of those factors.

The cells need to know what pathways their neighbors are expressing.

Put another way:Its like taking you in the middle of the night, out of your bed, taking off your clothes, cutting off parts of your arms and legs, pushing you through a screen door and throwing you out in the middle of the ocean and saying act like you, conduct yourself like you, Lough said earnestly.

PolarityTE will relocate you, your family, and your house. Its first product, for skin regeneration, starts with just a small piece of healthy skin taken from a patient with extensive burns. The sample is shipped to the companys facility in Salt Lake City, Utah, where it is processed into a paste to cover the wound. The paste contains so-called Minimally Polarized Functional Units (MPFUs) that instinctively organize and propagate to help heal a wound. The turnaround time is just 24-48 hours and the use of the patients own tissue obviates the risk of immune rejection.

With this new take on an old skin graft approach, PolarityTE aims to capture the diversity of the tissue ecosystem, with epidermal, dermal, and hypodermal cells, fibroblasts, hair follicles even the structural organization and blood vessel integration seen in the natural skin.

Of note, the technology pays special attention to the edges of the wound where the real healing occurs, its not a single cell that jumps between the margins, Lough said.

Its still early days, but the path-to-market is fast for an autologous (self) tissue transplant. FDA doesnt even require human trials for its regulatory clearance. To that end, the company recently announced the successful grafting of regenerated full-thickness, organized skin and hair follicles in third-degree burn wounds in pigs. The team is now looking ahead to a first-in-human trial in the third-quarter of 2017 and a possible roll out of the product early next year.

It would be a mistake, however, to place PolarityTE in the bucket of skin grafts only. Lough hopes the technology can go much further, to regenerate and restore bone, muscle, fascia, cartilage, and nerve tissues.

Photo: VolodymyrV, Getty Images

Continued here:
Reinventing tissue regeneration, one layer at a time - MedCity News

Posted in Utah Stem Cells | Comments Off on Reinventing tissue regeneration, one layer at a time – MedCity News

Q Therapeutics Expands Board of Directors With Appointment of Dr. Tom Parks as Independent Member – Marketwired (press release)

Posted: August 12, 2017 at 6:41 am

Appointment Adds World Class Expertise in Neuro-Cellular Interactions and functions

SALT LAKE CITY, UT--(Marketwired - Aug 7, 2017) - Q Therapeutics, Inc., developer of clinical-stage cell therapies for central nervous system (CNS) disease and injury, announced the appointment of Tom Parks, Ph.D. as an independent member to the Company's Board of Directors.In addition, Dr. Parks has agreed to serve on the Board's Nominating and Governance Committee; and will be joined on the Committee by current independent directors, Peter Barton Hutt, Peter Grebow, and Hunter Jackson.

Dr. Parks brings to Q Therapeutics more than 30 years experience in life science research and its translation into therapeutic products. As a faculty member in the Department of Neurobiology & Anatomy at the University of Utah School of Medicine from 1978, he conducted a long-term NIH-funded research program on development of the central auditory nervous system and served as chair of that department from 1992-2007. He was a co-founder of NPS Pharmaceuticals, Inc. and served on its board from 1986-2006. From 2008-2016, Dr. Parks was Vice President for Research and President of the Research Foundation for the University of Utah. He currently serves on the boards of Navigen Pharmaceuticals Inc., SentrX Animal Care Inc., and ConusRx Inc. He is a Fellow of the National Academy of Inventors and a recipient of the Utah Governor's Medal for Science and Technology. Dr. Parks earned a Bachelor of Science degree in Biology from the University of California at Irvine, a Ph.D. in Psychobiology from Yale University, and completed postdoctoral work at the University of Virginia School of Medicine.

"We are very pleased to welcome Dr. Parks to our Board of Directors. He brings tremendous expertise in the field of central nervous system development and the conditions leading to establishment of functional connections between neurons. We expect that Dr. Parks will prove of immeasurable value to Q Therapeutics as we continue to advance our first product, Q-Cells, through clinical development as well as development of our second generation induced pluripotent cell (iPSC) products," stated Steven Borst, President and Chief Executive Officer of Q Therapeutics.

About Q Therapeutics, Inc. -- Headquartered in Salt Lake City, Q Therapeutics is a clinical-stage company developing adult stem cell therapies to treat debilitating central nervous system (CNS) disease and injury. The Company's first therapeutic product candidate, Q-Cells, is intended to restore or preserve normal CNS activity by supplying essential nerve cell functions. Q-Cells may be suitable to treat a range of CNS disorders, including demyelinating conditions such as multiple sclerosis (MS), transverse myelitis , cerebral palsy and stroke, as well as other neurodegenerative diseases and injuries such as Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig's disease), Huntington's disease, spinal cord injury, traumatic brain injury, and Alzheimer's disease.Q Therapeutics' initial clinical targets are TM and ALS, with INDs in both indications now allowed to proceed by the FDA. The Company's proprietary product pipeline also includes neural cell products derived from induced pluripotent stem cells (iPSC). For more information, see http://www.qthera.com.

Cautionary Statement Regarding Forward Looking Information -- This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Q Therapeutics' technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of its intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect results and other risks and uncertainties are detailed from time to time in Q Therapeutics' periodic reports.

Go here to see the original:
Q Therapeutics Expands Board of Directors With Appointment of Dr. Tom Parks as Independent Member - Marketwired (press release)

Posted in Utah Stem Cells | Comments Off on Q Therapeutics Expands Board of Directors With Appointment of Dr. Tom Parks as Independent Member – Marketwired (press release)

Hispanics left out of clinical trials and cutting-edge treatments – Wisconsin Gazette

Posted: August 12, 2017 at 6:40 am

Two decades ago, Luis Antonio Cabrera received devastating news: He likely had only three months to live.

The Puerto Rican truck driver, then 50, had attributed his growing leg pain to spending so many hours on the road. The real culprit was a malignant tumor in his left kidney that was pressing on nerves from his lower spine.

His initial treatment involved removing the organ, a complex surgery that proved insufficient, as the cancerous cells had already spread to his lungs. His primary care physician in Puerto Rico contacted doctors at the National Institutes of Health, in Bethesda, Maryland, to enroll Cabrera in a medical study to test an innovative therapy: transplanting blood stem cells to destroy the cancer cells.

Today, at 70, Cabrera a father of five and grandparent who moved to West Virginia with his wife to be closer to NIH feels strong and healthy.

I come to do tests every six months Im like a patient at large, he said.

However, Cabrera is one of a relatively small number of Hispanics who participate in clinical trials.

Less than 8 percent of enrollees are Hispanic, even though Hispanics comprise 17 percent of the population, said Dr. Eliseo Prez-Stable, director of NIHs National Institute on Minority Health and Health Disparities.

That means not only do Hispanics have less access to experimental, cutting-edge treatments, but also that researchers have less data on how a drug works in that population.

Studies have shown that different ethnic groups can respond differently to the same treatment.

The lack of patients from minority groups is an endemic problem in clinical trials; minorities typically are represented at a very low rate.

Studies should represent the demographics of the country, said Dr. Jonca Bull, an assistant commissioner on minority health at the U.S. Food and Drug Administration. We need to close that gap so we can better understand how a particular drug or therapy works in different communities.

There are many reasons why Hispanic people do not enroll in these studies, Prez-Stable said: lack of information, disparities in access to health care and lack of fluency in English are among main factors.

Dr. Otis Brawley, chief medical officer with the American Cancer Society, said Latinx families are open to participating in clinical trials, especially to help treat a sick son or daughter, but they need a doctor to initiate and navigate the process.

Federal officials aim to augment Hispanic enrollment in clinical trials.

In March, the FDA launched a campaign to educate Hispanics about medical studies. Primary care physicians have to be the champions. In addition, the community health centers can help, because they are places of care that people trust, said Bull.

As of early July, there were 94,545 ongoing clinical trials in the United States, according to the NIHs official website, clinicaltrials.gov. As in Cabreras case, the primary physician usually helps a patient find a medical study, although the advent of the internet in recent decades has meant a growing number of patients discover trials themselves online.

The American Cancer Society also has an information service to help patients find clinical trials that match their medical condition. This service is available in Spanish.

To participate in a trial, a person must meet the researchers criteria for eligibility, including factors like age, gender or condition. Often, the center conducting the study covers related costs of drugs, treatments and tests.

For Brenda Aldana, receiving care at Holy Cross Hospital in Silver Spring, Maryland, made all the difference.

Aldana, 34, arrived in the United States from El Salvador nine years ago. During her first year here, she felt tired and her hair began to fall out. She initially thought those were symptoms of the stress of starting a new life in a new country, but while visiting her sister in Frederick, Maryland, Aldana fainted. It turned out she was suffering more than nerves: She had a pulmonary embolism.

Within two weeks of tests, she was diagnosed with lupus, a debilitating chronic condition with a high incidence among Latinas.

At Holy Cross, the doctors told me that they were going to help me get into a medical program for a medication to treat arthritis (caused by her lupus), said Aldana, who has three children, ages 17, 6 and 5.

Aldana travels from Olney, Maryland, to the NIH Clinical Center once a month to receive intravenous medication.

These days, Hispanics receive less quality medical care, so its important for them to be more involved in clinical trials, said Brawley, noting that enrolling in a clinical trial gives patients access to high-quality physicians they might not otherwise see.

In a medical study, instead of having the opinion of a single doctor, youll get the opinion of a group of highly qualified doctors who can say, This is good for people like you, Brawley said.

John Vasquez, 21, of San Antonio, Texas, needed only internet access and a cellphone to find the medical study that could change his life.

In September 2015, while on his way to his brothers football game, he lost feeling in his leg, arm and the right side of his face. I thought I was having a stroke, he said.

He had aplastic anemia, a potentially deadly, rare blood disorder that was destroying his red and white cells and his platelets, which aid the bodys clotting mechanism.

In a Facebook group for people with severe blood conditions, he was advised to contact the NIH, which sent him a kit for blood tests. After analyzing his clinical history, they told him he was eligible to participate in a medical study, which opened the gates to an innovative transplant that could change the course of his disease. Temporarily living with a sister in Maryland, he was scheduled for a bone marrow transplant this month. His donor: his 14-year-old brother.

Kaiser Health News is a national health policy news service. It is an editorially independent program of the Henry J. Kaiser Family Foundation.

More:
Hispanics left out of clinical trials and cutting-edge treatments - Wisconsin Gazette

Posted in West Virginia Stem Cells | Comments Off on Hispanics left out of clinical trials and cutting-edge treatments – Wisconsin Gazette

Woodrow Wilson baseball field to be renamed for Tom Parham – Beckley Register-Herald

Posted: August 12, 2017 at 6:40 am

Tom Parham remembers the time his Woodrow Wilson baseball team was playing Class AAA power Huntington East.

It was 1980, and the Flying Eagles were hosting the Pony Express at Harry Lewin Field. Not known to be a cavernous venue, the field lent itself to an offensive barrage and Huntington East was the last team standing.

A few weeks later, Parham led Woodrow to the state championship game and a rematch with the Express. Woodrow fell short again, but this time it was by the more purist-friendly score of 2-1.

It was then that Parham knew the Eagles needed a new field.

In stepped Doug Epling, Beckley businessman and community leader. He would later be known for refurbishing the old East Bank High School field for WVU Tech to use, as well as the construction of Linda K. Epling Stadium in Beckley, the home of the West Virginia Miners.

The latter, of course, bears the name of Epling's wife. The Tech field is named for Epling himself.The field he helped build on the Woodrow Wilson campus doesn't have an official name.

That will change Saturday.A ceremony will be held at 2 p.m. in the school cafeteria to officially rename the field for Thomas Parham.

The effort to honor the longtime coach was started by Sheila Brown.

"Words cannot describe how it feels," Parham said. "When Mrs. Brown started talking about it, I always told her, nah (modestly). I just thought, 'Let it go.' And finally she told me in April, 'Well, I'm going to the board. I'm going to ask them.' So she did and they told her what to do (at the next meeting)."

The Raleigh County School Board laid out a plan for Brown, and at the next meeting former coaches, colleagues and friends voiced their support.

Legendary boys basketball coach Dave Barksdale. State championship-winning football coach Pete Culicerto. Fellow New Hope Baptist Church member C.W. Claytor. Even Epling himself. They all showed up to see that Parham got the respect they feel he deserves.

"It was just touching to hear former coaches Coach Barksdale, Coach Culicerto, and I even heard from one of my coaching buddies from out of town, Ron Rose," Parham said. "He told Pete what (he wanted) to say. It was just touching, and a humbling experience."

Parham is being recognized for a career that spanned nearly three decades. He was hired as a biology teacher by Ross Hutchens before the start of the 1974-75 academic year.

"He said, 'I need a good biology teacher. I can get a coach anywhere,'" Parham said, laughing.

His first season as head baseball coach was 1975, and he remained there until his retirement in 2000. Along the way, his teams rolled up over 200 wins and appeared in the state tournament five times. Two of those trips resulted in runner-up finishes the 1980 meeting with Huntington East, and in 1983 against Martinsburg.

And the list of star players Parham coached seems endless Chuck Tate, Andy "Bam Bam" Wakefield, Larry Maiolo, Mason Basham, Larry Hickman, Joe Joe Maiolo, Larry Pat Farley, Phil Culicerto, Tim Epling, Phil Lane, Ronnie Fama, John O'Dell.

There were many others, and many of themare members of the Woodrow Wilson Baseball Hall of Fame.

"I was fortunate I came across some good ball players," Parham said. "You don't like to toot your own horn, but like a fella said, we put Woodrow Wilson baseball on the map."

Another was Ronnie Scott, who went on to work for NASA in Florida before returning to Beckley in 2010. Sadly, he passed away in May at age 59.

"He wanted to see baseball dominant again like it was when he played," Parham said.

When Parham retired from baseball in 2000 he stayed on as a biology teacher for one more year it was the emphatic end of an era at the school. Not only did Parham retire, but Culicerto retired after the 1999 football season, and Barksdale left the bench just months before Parham to take a coaching job in Aiken, S.C.

"Indeed it was," said Parham, now 74. "I enjoyed working with Coach Culicerto (as an assistant football coach). He was a great football coach, and he was a baseball supporter. He had seven sons play baseball for me. Three of them played in the state tournament."

After his retirement, Parham's was a familiar face in the stands at Woodrow baseball games. But in 2009, his ability to be a spectator slowed down when it was discovered that he had cancer.

Parham was diagnosed with multiple myeloma, a blood cancer that develops in the plasma cells located in bone marrow. The cancer did eventually go into remission, but Parham was still getting checkups when something told him he needed to go to Johns Hopkins in Baltimore.

It was there that he was introduced to autologous stem cell transplant. It's a procedure that involves collecting the patient's stem cells and following it up with high doses of chemotherapy or a combination of chemo and radiation. The process kills cancer cells while also killing blood-producing cells left in the bone marrow.

The collected stem cells are later transplanted back into the patient, allowing the marrow to produce new blood cells.

"I met a very interesting and a caring doctor up there, Dr. (Ivan) Borrello. He told me (about the transplant)," Parham said. "As a matter of fact, they have been doing this since 1980. He asked, 'What do you think about a stem cell transplant?' And I said yeah. Anything to get rid of this cancer.

"At that time my cancer was in remission, so he couldn't do anything. He said we would have to wait until it comes back. He hoped it didn't come back, but if it does ..."

It did, and in February he had the procedure performed.

"It came back in 2016, and when you're over 70 they don't usually do these things," Parham said. "But he felt like I was in good shape, which I think well, I know I am. I went through it, successful, no problems whatsoever.

"After teaching biology, I thought I knew some things. Now I know I know some things."

Just like baseball.

Email: gfauber@register-herald.com and follow on Twitter @GaryFauber

Read the original post:
Woodrow Wilson baseball field to be renamed for Tom Parham - Beckley Register-Herald

Posted in West Virginia Stem Cells | Comments Off on Woodrow Wilson baseball field to be renamed for Tom Parham – Beckley Register-Herald

Stem cells may treat lung fibrosis diseases – Futurity: Research News

Posted: August 11, 2017 at 6:45 am

Researchers have taken a step towards a possible treatment for several often-fatal lung conditions that affect millions of Americanssuch as idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and cystic fibrosisby harvesting and using lung stem cells.

In research appearing in the journal Respiratory Research, the scientists demonstrated that they could harvest lung stem cells from people using a relatively non-invasive, doctors-office technique. They were then able to multiply the harvested lung cells in the lab to yield enough cells sufficient for human therapy.

In a second study, which appears in the journal Stem Cells Translational Medicine, the team showed that, in rodents, they could use the same type of lung cell to successfully treat a model of IPFa chronic, irreversible, and ultimately fatal disease characterized by a progressive decline in lung function.

The researchers have been in discussions with the FDA and are preparing an application for an initial clinical trial in patients with IPF.

This is the first time anyone has generated potentially therapeutic lung stem cells from minimally invasive biopsy specimens, says co-senior author of both papers Jason Lobo, an assistant professor of medicine at the University of North Carolina at Chapel Hill and medical director of lung transplant and interstitial lung disease.

We think the properties of these cells make them potentially therapeutic for a wide range of lung fibrosis diseases.

Co-senior author Ke Cheng, an associate professor in North Carolina State Universitys molecular biomedical sciences department and UNC/NCSUs joint biomedical engineering department, says, We think the properties of these cells make them potentially therapeutic for a wide range of lung fibrosis diseases.

These diseases of the lung involve the buildup of fibrous, scar-like tissue, typically due to chronic lung inflammation. As this fibrous tissue replaces working lung tissue, the lungs become less able to transfer oxygen to the blood. Patients ultimately are at risk of early death from respiratory failure.

In the case of IPF, which has been linked to smoking, most patients live for fewer than five years after diagnosis.

The two FDA-approved drug treatments for IPF reduce symptoms but do not stop the underlying disease process. The only effective treatment is a lung transplant, which carries a high mortality risk and involves the long-term use of immunosuppressive drugs.

Scientists have been studying the alternative possibility of using stem cells to treat IPF and other lung fibrosis diseases. Stem cells are immature cells that can proliferate and turn into adult cells in order to, for example, repair injuries. Some types of stem cells have anti-inflammatory and anti-fibrosis properties that make them particularly attractive as potential treatments for fibrosis diseases.

Cheng and Lobo have focused on a set of stem cells and support cells that reside in the lungs and can be reliably cultured from biopsied lung tissue. The cells are called lung spheroid cells for the distinctive sphere-like structures they form in culture.

As the scientists reported in an initial paper in 2015, lung spheroid cells show powerful regenerative properties when applied to a mouse model of lung fibrosis. In their therapeutic activity, these cells also outperform other non-lung-derived stem cells known as mesenchymal stem cells, which are also under investigation to treat fibrosis.

In the first of the two new studies, Lobo and his team showed that they could obtain lung spheroid cells from human lung disease patients with a relatively non-invasive procedure called a transbronchial biopsy.

We snip tiny, seed-sized samples of airway tissue using a bronchoscope, Lobo says. This method involves far less risk to the patient than does a standard, chest-penetrating surgical biopsy of lung tissue.

Cheng and his colleagues cultured lung spheroid cells from these tiny tissue samples until they were numerous enoughin the tens of millionsto be delivered therapeutically. When they infused the cells intravenously into mice, they found that most of the cells gathered in the animals lungs.

These cells are from the lung, and so in a sense theyre happiest, so to speak, living and working in the lung, Cheng says.

For the second study, the researchers first induced a lung fibrosis condition in rats. The condition closely resembled human IPF. Then the researchers injected the new cultured spheroid cells into one group of rats. Upon studying this group of animals and another group treated with a placebo, the researchers saw healthier overall lung cells and significantly less lung inflammation and fibrosis in the rats treated with lung spheroid cells.

Our vision is that we will eventually set up a universal cell donor bank

Also, the treatment was safe and effective whether the lung spheroid cells were derived from the recipients own lungs or from the lungs of an unrelated strain of rats, Lobo says. In other words, even if the donated stem cells were foreign, they did not provoke a harmful immune reaction in the recipient animals, as transplanted tissue normally does.

Lobo and Chen expect that when used therapeutically in humans, lung spheroid cells initially would be derived from the patient to minimize any immune-rejection risk. Ultimately, however, to obtain enough cells for widespread clinical use, doctors might harvest them from healthy volunteers, as well as from whole lungs obtained from organ donation networks. The stem cells could later be used in patients as-is or matched immunologically to recipients in much the same way transplanted organs are typically matched.

Our vision is that we will eventually set up a universal cell donor bank, Cheng says.

Cheng, Lobo, and their teams are now planning an initial study of therapeutic lung spheroid cells in a small group of IPF patients and expect to apply later this year for FDA approval of the study. In the long run, the scientists hope their lung stem cell therapy will also help patients with other lung fibrosis conditions of which there are dozens, including COPD, cystic fibrosis, and fibro-cavernous pulmonary tuberculosis.

Additional researchers contributing to this work are from UNC, NC State, the joint UNC-NC State biomedical engineering department, and two hospitals in Shijiazhuang, China. The National Institutes of Health, the UNC General Assembly Research Opportunities Initiative, and the NC State Chancellors Innovation Fund funded this research.

Source: UNC-Chapel Hill

See the original post:
Stem cells may treat lung fibrosis diseases - Futurity: Research News

Posted in North Carolina Stem Cells | Comments Off on Stem cells may treat lung fibrosis diseases – Futurity: Research News

Lung fibrosis? Stem cell therapy holds promise – The Hindu – The Hindu

Posted: August 11, 2017 at 6:45 am

A team of scientists from the UNC School of Medicine and North Carolina State University (NCSU), U.S. have developed promising research towards possible stem cell treatment for several lung conditions, such as idiopathic pulmonary fibrosis (IPF), chronic obstructive pulmonary disease (COPD), and cystic fibrosis, all of which are known to be fatal conditions. In the journal Respiratory Research, the scientists demonstrated that they could harvest lung stem cells from people using a relatively non-invasive, doctors office technique. They were then able to multiply the harvested lung cells in the lab to yield enough cells sufficient for human therapy.

In a second study, published in the journal Stem Cells Translational Medicine, the team showed that in rodents they could use the same type of lung cell to successfully treat a model of IPF a chronic, irreversible, and ultimately fatal disease characterised by a progressive decline in lung function. These diseases of the lung involve the build-up of fibrous, scar-like tissue, typically due to chronic lung inflammation. As this fibrous tissue replaces working lung tissue, the lungs become less able to transfer oxygen to the blood. Patients ultimately are at risk of early death from respiratory failure. In the case of IPF, which has been linked to smoking, most patients live for fewer than five years after diagnosis.

See the rest here:
Lung fibrosis? Stem cell therapy holds promise - The Hindu - The Hindu

Posted in North Carolina Stem Cells | Comments Off on Lung fibrosis? Stem cell therapy holds promise – The Hindu – The Hindu

Page 1,494«..1020..1,4931,4941,4951,496..1,5001,510..»